Zomedica Corp. (NYSEAMERICAN:ZOM – Free Report) – Analysts at Noble Financial issued their FY2024 earnings estimates for shares of Zomedica in a research report issued on Monday, November 11th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings per share of ($0.05) for the year. Noble Financial has a “Strong-Buy” rating on the stock. Noble Financial also issued estimates for Zomedica’s Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.03) EPS.
Zomedica Price Performance
Shares of ZOM stock opened at $0.15 on Thursday. Zomedica has a fifty-two week low of $0.12 and a fifty-two week high of $0.23.
Institutional Inflows and Outflows
Zomedica Company Profile
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.
See Also
- Five stocks we like better than Zomedica
- What is the Dow Jones Industrial Average (DJIA)?
- Shopify Stock Rally Continues: Why the Growth Story Isn’t Over
- NYSE Stocks Give Investors a Variety of Quality Options
- Tariff Troubles: 3 Stocks Planning Higher Prices
- How is Compound Interest Calculated?
- Mercer Near Rock Bottom: Is This High-Yield Play Set to Soar?
Receive News & Ratings for Zomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zomedica and related companies with MarketBeat.com's FREE daily email newsletter.